Literature DB >> 10429627

Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.

G Saeter1, T Wiebe, T Wiklund, O Monge, Y Wahlqvist, K Engström, E Forestier, T Holmström, A E Stenwig, H Willén, O Brosjö, G Follerås, T A Alvegård, H Strander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10429627

Source DB:  PubMed          Journal:  Acta Orthop Scand Suppl        ISSN： 0300-8827


× No keyword cloud information.
  6 in total

Review 1.  Methotrexate for high-grade osteosarcoma in children and young adults.

Authors:  Elvira C van Dalen; Jorrit W van As; Beatriz de Camargo
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

2.  Protein phosphatase 2A Cα regulates proliferation, migration, and metastasis of osteosarcoma cells.

Authors:  Di Yang; Hirohiko Okamura; Hiroyuki Morimoto; Jumpei Teramachi; Tatsuji Haneji
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

3.  Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience.

Authors:  Liliana Vasquez; Fanny Tarrillo; Monica Oscanoa; Ivan Maza; Jenny Geronimo; Gloria Paredes; Jose María Silva; Luis Sialer
Journal:  Front Oncol       Date:  2016-02-02       Impact factor: 6.244

4.  Chemotherapy in primary osteogenic sarcoma in patients over the age of forty.

Authors:  Bulent Ozkurt; Kerem Basarir; Bulent Yalcin; Abdullah Merter; Yusuf Yildiz; Yener Saglik
Journal:  Acta Orthop Traumatol Turc       Date:  2017-02-16       Impact factor: 1.511

5.  Comparison of the outcome of conventional osteosarcoma at two specialist international orthopaedic oncology centres.

Authors:  Samuel Ford; Adnan Saithna; Robert J Grimer; Piero Picci
Journal:  Sarcoma       Date:  2004

Review 6.  A comparative study between limb-salvage and amputation for treating osteosarcoma.

Authors:  Xiaojuan Li; Ya Zhang; Shanshan Wan; Huiling Li; Dongqi Li; Junfeng Xia; Zhongqin Yuan; Mingyan Ren; Shunling Yu; Su Li; Yihao Yang; Lei Han; Zuozhang Yang
Journal:  J Bone Oncol       Date:  2016-01-23       Impact factor: 4.072
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.